I
33.67
0.06 (0.19%)
| Previous Close | 33.60 |
| Open | 33.99 |
| Volume | 400,443 |
| Avg. Volume (3M) | 2,120,561 |
| Market Cap | 4,208,947,712 |
| Price / Earnings (TTM) | 34.35 |
| Price / Earnings (Forward) | 10.36 |
| Price / Sales | 3.64 |
| Price / Book | 145.25 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -5.30% |
| Operating Margin (TTM) | 25.56% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | -6.30% |
| Quarterly Earnings Growth (YOY) | -23.00% |
| Current Ratio (MRQ) | 0.880 |
| Operating Cash Flow (TTM) | 135.00 M |
| Levered Free Cash Flow (TTM) | 264.88 M |
| Return on Assets (TTM) | 12.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Indivior PLC | Bullish | Bullish |
AIStockmoo Score
1.6
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.63 |
|
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 4.02% |
| % Held by Institutions | 89.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Madison Avenue Partners, Lp | 30 Sep 2025 | 6,463,585 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 41.00 (Piper Sandler, 21.79%) | Buy |
| Median | 38.00 (12.88%) | |
| Low | 35.00 (HC Wainwright & Co., 3.97%) | Buy |
| Average | 38.00 (12.88%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 29.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 31 Oct 2025 | 41.00 (21.79%) | Buy | 29.37 |
| HC Wainwright & Co. | 30 Oct 2025 | 35.00 (3.97%) | Buy | 29.13 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2025 | Announcement | Indivior Concludes Legacy U.S. Department of Justice Matter |
| 19 Nov 2025 | Announcement | Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 03 Nov 2025 | Announcement | Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine |
| 30 Oct 2025 | Announcement | Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance |
| 28 Oct 2025 | Announcement | Indivior to Participate in the Stifel 2025 Healthcare Conference |
| 16 Oct 2025 | Announcement | Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th |
| 15 Oct 2025 | Announcement | Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment |
| 01 Oct 2025 | Announcement | Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |